Melatonin plays an important role in the regulation of retinal functions, and previous studies have also reported that the action of melatonin on photoreceptors is mediated by melatonin receptor heterodimers. Furthermore, it has been reported that the melatonin-induced increase in the amplitude of the a-and b-wave is significantly blunted by inhibition of PKC. Previous work has also shown that PKCζ is present in the photoreceptors, thus suggesting that PCKζ may be implicated in the modulation of melatonin signaling in photoreceptors. To investigate the role PKCζ plays in the modulation of the melatonin effect on the scotopic ERG, mice were injected with melatonin and with specific inhibitors of different PKC isoforms. PKCζ knockout mice were also used in this study. PKCζ activation in photoreceptors following melatonin injection was also investigated with immunocytochemistry. Inhibition of PKCζ by PKCζ-pseudosubstrate inhibitor (20 μM) significantly reduced the melatonin-induced increase in the amplitude of the a-and b-wave. To further investigate the role of different PKCs in the modulation of the ERGs, we tested whether intra-vitreal injection of Enzastaurin (a potent inhibitor of PCKα, PKCβ, PKCγ, and PKCε) has any effect on the melatonin-induced increase in the a-and b-wave of the scotopic ERGs. Enzastaurin (100 nM) did not prevent the melatonin-induced increase in the amplitude of the awave, thus suggesting that PCKα, PKCβ, PKCγ, and PKCε are not involved in this phenomenon. Finally, our data indicated that, in mice lacking PKCζ, melatonin injection failed to increase the amplitude of the a-and b-waves of the scotopic ERGs. An increase in PKCζ phosphorylation in the photoreceptors was also observed by immunocytochemistry. Our data indicate that melatonin signaling does indeed use the PKCζ pathway to increase the amplitude of the a-and b-wave of the scotopic ERG.
Introduction
In the mammalian retina, the hormone melatonin is synthetized by retinal photoreceptors during the night, and many studies have now demonstrated that melatonin plays a role in the regulation of many retinal functions (Wiechmann and Summers, 2008; Tosini et al., 2012) and can protect photoreceptors from apoptosis in mouse models of retinitis pigmentosa (Liang et al., 2001; Xu et al., 2017) or their viability during aging (Baba et al., 2009; Gianesini et al., 2016) . A previous investigation has reported that melatonin acts on the photoreceptor via melatonin receptors' heterodimer (MT 1/2h ) and is involved the activation of PKC, as a melatonin-induced increase in the amplitude of the aand b-wave is significantly blunted by inhibition of PKC (Baba et al., 2013) .
Among the several PKC isoforms that are expressed in the retina (Koike et al., 2005; Lee et al., 2007) , PKCζ and PKCλ are primarily expressed in the photoreceptors (Ghalayini et al., 1994; Lee et al., 2007; Omri et al., 2013) . PKCλ is involved in photoreceptor development (Koike et al., 2005; Pinzon-Guzman et al., 2011) , and, because melatonin receptors knock-out mice show normal retinal development, we believe that this isoform is unlikely to mediate MT 1 / 2h signaling. Thus, we hypothesize that PKCζ may be an isoform that is involved in the modulation of melatonin signaling in the photoreceptors. PKCζ is an atypical isoform of PKC that is not activate by calcium or diacylglycerol, but it is believed to rely on a second messenger generated through the phosphoinositide 3-kinase (PI3-K).
Although PKCζ is present in photoreceptors, its role is still not well defined. Lee et al. (2007) reported that, also in mice retinas, PKCζ is mostly present in the inner and outer segments where it co-localizes with CaBP4 -a subfamily of neuronal Ca 2+ -binding proteins -and it is https://doi.org/10.1016/j.exer.2018.07.026 Received 31 March 2018; Received in revised form 5 July 2018; Accepted 25 July 2018 involved in the phosphorylation of CaBP4. A more recent study has implicated PKCζ in the pathology of diabetic retinopathy; most specifically, it was reported that PKCζ labeling in the cone photoreceptors was lost, and cone structure was altered in rats by hyperglycemia (Omri et al., 2013) , thus suggesting that this PKC may represent a possible target to prevent the development of diabetic retinopathy. The aim of the present study was to investigate the role of PKCζ in the modulation of the melatonin-induced increase in the amplitude of the a-and b-wave of the scotopic ERG in mouse.
Materials and methods

Animals
) mice (three to four months old) were used in this study. Mice were maintained in 12 h light and 12 h dark with lights on (zeitgeber time [ZT] 0) at 06:00 a.m. and lights off (ZT 12) at 6:00 p.m. The light was supplied with fluorescent tubes and the light intensity ranged from 200 to 400 lux at cage level. The genotypes were determined according to the protocols previously described (Baba et al., 2013) . We have previously reported that although C57/BL/6 mice are unable to synthetize melatonin (Ebihara et al., 1986 ) administration of exogenous melatonin still increases the amplitude of the a-and b-wave of the scotopic ERG via activation of MT 1/2h (Baba et al., 2013) . Therefore, instead to produce a PKCζ KO mouse in a C3H-f +/+ , we decided to investigate the effect that administration of exogenous melatonin will produce of the amplitude of the scotopic ERG in mice lacking PKCζ in a C57/BL6J genetic background. All the experimental procedures were carried out in accordance with Association for Assessment of Laboratory Animal Care policies and approved by the Morehouse School of Medicine Animal Care and Use Committee.
Scotopic electroretinogram (ERG)
The scotopic ERGs were performed on anesthetized (ketamine: 80 mg/kg; and xylazine: 16 mg/kg) mice as described in our previous publications (Baba et al., 2009 (Baba et al., , 2013 . To determine the photoreceptors' response to the different experimental treatments we measured the amplitude of the a-wave 7 ms after the initial flash of light (Peachey et al., 2012; Baba et al., 2013) .
Melatonin (Sigma, St Luis, MO) was dissolved in ethanol and then diluted with sterilized PBS. Melatonin was administered by intraperitoneal (1 mg/kg i. p.) or intravitreal (i.v. in various dosages) injection. PKCζ-pseudosubstrate (ApexBio Tech, Houston, TX) was dissolved with 150 ml of acetonitrile and 350 ml of ddH2O. The solution was diluted with PBS to make a 400 μM solution. The volume of 1 μl was intravitreally injected in one eye (final concentration of 20 μM) using a 10 μl Hamilton syringe (Hamilton Company, Reno Nevada). The same volume of vehicle (30% acetonitrile) was injected into the other eye. Enzastaurin (ApexBio Tech, Houston, TX) was first dissolved in DMSO to make a 10 mM solution and diluted with PBS to make a 2 μM working solution. The volume of 1 μl was intravitreally injected into one eye (final concentration of 100 nM) using a 10 μl Hamilton syringe (Hamilton Company, Reno Nevada). The same volume of vehicle (0.2% DMSO) was injected into the other eye (see Baba et al., 2013 for further details). All melatonin injections were given at ZT5 (i.e., 11:00 a.m.) when the endogenous melatonin level was low and ERGs were performed at ZT 6.
Immunohistochemistry
Eyes for immunohistochemistry were isolated and fixed in paraformaldehyde (PAF) 4% for 1 h and cryoprotected in sucrose 30% overnight at 4°C. Cryosections (14 μm thick) were washed three times for 10 min in PBS and then incubated for 45 min in 1% bovine serum albumin (BSA) and 0.4% Triton-X100 in PBS to permeabilize membranes and block unspecific binding. Sections were incubated overnight at 4°C with primary antibodies diluted in 1% BSA and 0,03% Triton-100 (see Table 1 ), washed in PBS, and then incubated for 2 h at room temperature in secondary antibody (anti-rabbit conjugated with Alexa Fluor 488, 1:1000 Molecular Probes) diluted in 1% BSA in PBS. Nuclear staining was obtained with propidium iodide. After washing in PBS, they were cover-slipped with Vectashield (Vector Laboratories). Retinal sections were visualized with a confocal microscope (Zeiss LSM700); files were processed with image manipulation software (GIMP2.8.18).
Results
3.1. Inhibition of PKCζ blocks the melatonin-induced increase in the a-and b-wave of the scotopic ERG Fig. 1 shows the results obtained by inhibiting different PKC isoforms. Inhibition of PKCζ by PKCζ-pseudosubstrate inhibitor (20 μM) blocked the melatonin-induced increase in the amplitude of the a-and b-wave (two-way ANOVA, p < 0.01). To further investigate the role of different PKCs in the modulation of the ERGs, we tested whether intravitreal injection of Enzastaurin (a potent inhibitor of PCKα, PKCβ, PKCγ, and PKCε) has any effect on the melatonin-induced increase in the a-and b-wave of the scotopic ERGs. Enzastaurin (100 nM) did not prevent the melatonin-induced increase in the amplitude of the a-wave (Fig. 2 , two-way ANOVA, p > 0.05), thus suggesting that inhibition of these isoforms PCKα, PKCβ, PKCγ, and PKCε are not involved in the modulation of the melatonin-induced increase of the a-wave of the scotopic ERG. The amplitude of the b-wave was significantly decreased in the mice-treated Enzastaurin (Fig. 2 , two-way ANOVA, p < 0.01).
3.2. Administration of melatonin in PKCζ KO mice does induce an increase in the amplitude of a-and b-wave of the scotopic ERG Fig. 3 shows the result obtained with PKCζ KO mice. The scotopic ERG of PKCζ KO mice did not differ from that of control mice (two-way ANOVA, p > 0.01), and -consistently with the result obtained with the PKCζ-pseudosubstrate inhibitor -melatonin injection (1 mg/kg) failed to induce an increase the amplitude of the a-and b-waves of the scotopic ERGs (Fig. 3 , two-way ANOVA, p > 0.01). Fig. 4 shows representative micrographs of retinal sections. Melatonin injection (i.p., 1 mg/kg) induced a significant increase in PKCζ phosphorylation in the photoreceptors (Fig. 4A) . No increase in the PKCζ phosphorylation was observed in MT 1 and MT 2 KO mice (B, C) or in mice that received the vehicle injection.
Administration of exogenous induces PKCζ phosphorylation in the photoreceptors
Discussion
Our previous work has shown that melatonin signaling via MT 1/2h plays an important role in the modulation of the scotopic ERGs (Baba et al., 2009 (Baba et al., , 2013 Sengupta et al., 2011) . The data presented in this study indicate that MT 1/2h signaling involves PKCζ because inhibition Experimental Eye Research 177 (2018) [50] [51] [52] [53] [54] of PCKζ activity via intravitreal injection of PKCζ-pseudosubstrate inhibitor or by genetic ablation of PKCζ completely abolished the increase of a-wave of the scotopic ERG (see Figs. 1-3) . The observation that the amplitude of the a-wave at 7 ms is already significantly affected by PKCζ inhibition or removal together with the localization PKCζ immunoreactivity within the inner and outer segments of the photoreceptors indicate that PKCζ acts at this level to modulate the action of melatonin. Our data also suggest that the other PKC isoforms are not implicated in the modulation of melatonin signaling at the level of the photoreceptors (i.e., a-wave), but a significant effect was observed at the levels of the b-wave. This result suggests that one of these PKC isoforms may be implicated in the regulation of the scotopic ERGs at the level of the inner retina. Further studies will be required to identify the specific PKC isoform that is responsible for such a phenomenon. Fig. 1 . Effect of PKCζ inhibition on the scotopic ERG. C3H mice were injected with melatonin (i.p. 1 mg/kg); then one eye was injected (i.v.) with PKCζ-pseudosubstrate inhibitor (i.v. 20 μM), while the other eye was injected with vehicle. PKCζ-pseudosubstrate inhibitor completely blocked the melatonin-induced increases in the amplitude of the 7 msec a-wave (A), a-wave (B), b-wave (C, two-way ANOVA p < 0.01). Black circles indicate PKCζ-pseudosubstrate inhibitor-treated eyes; white circles indicate vehicle-treated eyes. Each point represents the mean ± standard error of the mean (SEM, n = 6). Representative ERG traces for PKCζ-pseudosubstrate inhibitor (black) and vehicle (grey) treated eyes are shown in D. Fig. 2 . Effect of PCKα, PKCβ, PKCγ, and PKCε inhibition on the scotopic ERG. Mice were injected with melatonin (i.p. 1 mg/kg); then one eye was injected (i.v.) with Enzastaurin (100 nM), while the other eye was injected with vehicle. Enzastaurin did not block the melatonininduced increase in the amplitude a-wave (A and B, twoway ANOVA p > 0.05), but Enzastaurin blocked the increase in the amplitude of b-wave (C, two-way ANOVA p < 0.01). Black circles indicate Enzastaurin-treated eye; white circles indicate vehicle-treated eyes. Each point represents mean ± SEM (n = 4). Representative ERG traces for Enzastaurin (black) and vehicle (grey) treated eyes are shown in D.
The means by which melatonin may increase the photosensitivity of the photoreceptor is not known, but recent work in the frog Xenopus laevis has indicated that PLC-PKC signaling is involved in the light-dependent translocation of Arrestin1 in rod photoreceptors (Orisme et al., 2010) and our studies indicate that MT 1/2h does indeed signal via PLC-PKCζ; thus we would like to suggest that melatonin may increase photoreceptor photosensitivity by affecting the translocation of arrestin from the outer to the inner segments.
Our previous study shows that melatonin signaling is also involved in the modulating of photoreceptor viability during aging (Gianesini et al., 2016) . The mechanism by which melatonin signaling supports photoreceptor health involves activation during the night of the AKT-FOXO1 pathway with the consequent downregulation of the Fas-FasL signaling (Gianesini et al., 2016; Sánchez-Bretaño et al., 2017) . Because PKCζ is known to be involved in the phosphorylation of AKT (Bandyopadhyay et al., 2002) , it is possible to speculate that the decrease in the number of cones observed in MT 1 −/− and MT 2 −/− mice (Gianesini et al., 2016) may be a direct consequence of the lack of nocturnal activation of this PKC isoform. Indeed, a previous study has reported that downregulation of PKCζ may lead to change in cone structure and premature death of these cells (Omri et al., 2013) .
In conclusion, our study indicates that increase in the amplitude of the a-and b-wave of the scotopic ERGs that follow the administration of exogenous melatonin is mediated by PKCζ, as its inhibition or removal completely prevents the increase of the amplitude of the a-and b-wave. Further studies will be needed to identify the substrates activated by melatonin signaling via PCKζ in mice photoreceptors and the mechanism by which melatonin produces such an increase. In this context, it is important to mention that our laboratory has recently shown that melatonin receptors are present and functional in a photoreceptor-like cell line, 661 W (Sánchez-Bretaño et al., 2017) , where they seem to activate similar pathways of those activated in mice rods and cones. Fig. 3 . Melatonin administration does not induce an increase in the amplitude of the a-and b-wave of the scotopic ERG in PKCζ KO mice. PCKζ KO mice were injected with melatonin (i.p. 1 mg/kg) or vehicle. Melatonin did not induce an increase in the amplitude of the a-and b-wave of the scotopic ERG (C, two-way ANOVA p > 0.05). Black circles indicate melatonin-treated mice; white circles indicate vehicle-treated mice. Each point represents the mean ± SEM (n = 5). Representative ERG traces for PKCζ KO mice injected with melatonin (black) or vehicle (grey) are shown in D. Hence, the study of the substrate activated by PKCζ in photoreceptors may be facilitated by the use of these cells.
